Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis

Hepatology

Volumn 50, Issue 3, 2009, Pages 772-780

  Fujita, Koji ^a   Nozaki, Yuichi ^a   Wada, Koichiro ^b   Yoneda, Masato ^a   Fujimoto, Yoko ^c   Fujitake, Mihoyo ^c   Endo, Hiroki ^a   Takahashi, Hirokazu ^a   Inamori, Masahiko ^a   Kobayashi, Noritoshi ^a   Kirikoshi, Hiroyuki ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; PERILIPIN A; PERILIPIN B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOPROTEIN; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN TISSUE; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TRIACYLGLYCEROL BLOOD LEVEL; BIOSYNTHESIS; BLOOD; FATTY LIVER; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; DNA DAMAGE; FATTY LIVER; FEMALE; HUMANS; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PPAR ALPHA; TRIGLYCERIDES;

EID: 70349249503     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23094     Document Type: Article

References (28)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350.
2. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. HEPATOLOGY 2007;46:582-589. (Pubitemid 47344794)
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419 (Pubitemid 29258890)
4. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003;18:124-138.
5. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetalogia 1985;28:412-419. (Pubitemid 15018832)
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003;37:917-923. (Pubitemid 36397405)
7. Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007;27:708-715.
8. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004;27:187-195. (Pubitemid 38175204)
9. Fujita K, Nozaki Y, Yoneda M, Wada K, Saito S, Nakajima A. et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008;57:1583-1591.
10. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002;43:805-814. (Pubitemid 34477908)
11. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979;28:1086-1096.
12. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211:283-286. (Pubitemid 29161765)
13. 11C]- iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 2000;27:529-532.
14. Reske SN, Blumstein NM, Neumaier B, Gottfield HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-1254. (Pubitemid 47544875)
15. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Whitington PF, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004;287:1035-1043.
16. User Bulletin 2. ABI PRISM 7700 Sequence Detection System. Foster City, CA: Applied Biosystems; December 11, 1997 (updated October 2001).
17. Marshall SE, Welsh KI. Tumor necrosis factor polymorphisms and acute rejection: proven link or provisional association? Transplantation 2000;69: 1237-1239.
18. Zegarska J, Paczek L, Mroz A. Quantitative gene expression of TGF-β1, TNF-α, IL-1β and IL-6 in the renal artery wall of chronically rejected human renal allografts. Transpl Proc 2002;34:3176-3179. (Pubitemid 35463285)
19. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115: 1343-1351. (Pubitemid 40629054)
20. Lee RG, Shah R, Sawyer JK, Hamilton RL, Parks JS, Rudel LL, et al. ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res 2005;46:1205-1212. (Pubitemid 43109835)
21. Havel RJ. Lipoproteins and lipid transport. Adv Exp Med Biol 1975;63: 37-59.
22. Hermier D, Salichon MR, Guy G, Peresson R. Differential channeling of liver lipids in relation to susceptibility to hepatic steatosis in the goose. Poultry Sci 1999;78:1398-1406. (Pubitemid 129555747)
23. Yao Z, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 1988;263:2998-3004. (Pubitemid 18062955)
24. Li Z, Agellon LB, Vance DE. Phosphatidylcholine homeostasis and liver failure. J Biol Chem 2005;280:37798-37802.
25. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH. HEPATOLOGY 2007;45:1097-1107. (Pubitemid 46775771)
26. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. HEPATOLOGY 2002;35:898-904.
27. kura Y, Ohsawa M, Suekane T, Kawada N, Arakawa T, Ueda M, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. HEPATOLOGY 2006;43: 506-514.
28. Fujita K, Yoneda M, Wada K, Saito S, Terauchi Y, Nakajima A, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007;52:3455-3464. (Pubitemid 350077187)